Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
48 hedge funds and large institutions have $19.3M invested in Carisma Therapeutics in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 14 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
0% more funds holding
Funds holding: 48 → 48 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
0.76% less ownership
Funds ownership: 1.97% → 1.21% (-0.76%)
55% less capital invested
Capital invested by funds: $43.3M → $19.3M (-$24M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$720K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$216K |
| 3 |
CHP
Castle Hook Partners
New York
|
+$216K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$108K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$86.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$10.7M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.73M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.35M |
| 4 |
Millennium Management
New York
|
-$911K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
-$492K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Jane Street
New York
| – | -$41K | -1,429 | Closed |
|
52
Two Sigma Investments
New York
| – | -$34K | -1,212 | Closed |
|
53
Brown Advisory
Baltimore,
Maryland
| – | -$30K | -1,044 | Closed |
|
54
Invesco
Atlanta,
Georgia
| – | -$25K | -882 | Closed |
|
|
LC
55
Lindbrook Capital
Calabasas,
California
| – | -$14K | -500 | Closed |
|
|
CG
56
Cutler Group
San Francisco,
California
| – | -$3K | -123 | Closed |
|
57
Simplex Trading
Chicago,
Illinois
| – | +$17 | +1 | New |
|
58
Barclays
London,
United Kingdom
| – | +$173 | +10 | New |
|
CARM Hedge Fund Activity: Q1 2019 in Review
48 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2019, worth a combined $19.3M — down 55% from $43.3M a quarter earlier.
Fund positioning in CARM was balanced in Q1 2019: 14 funds opened new positions, 14 closed out, 11 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $720K. The largest seller was Consonance Capital Management, exiting entirely with an estimated $10.7M sold.
- 48 institutional investors held Carisma Therapeutics (CARM) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $19.3M of Carisma Therapeutics stock for Q1 2019, down 55% quarter-over-quarter.
- 14 funds opened new Carisma Therapeutics positions in Q1 2019 and 14 closed out, a net change of 0 holders.
- The largest Carisma Therapeutics buyer in Q1 2019 was Vanguard Group, an estimated $720K added.
- The largest Carisma Therapeutics seller in Q1 2019 was Consonance Capital Management, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2019.